Linked Life Data

19169046

Source:http://linkedlifedata.com/resource/pubmed/id/19169046

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-3-5
pubmed:abstractText
Standard treatment for patients with advanced colorectal cancer (ACRC) includes fluoropyrimidines in combination with oxaliplatin or irinotecan. The addition of targeted agents such as bevacizumab and cetuximab to these chemotherapy backbones further improved outcome with survival rates. However, even after intensive treatment, most tumors will subsequently progress and some patients are offered experimental phase I therapies.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1423-0232
pubmed:author
pubmed:copyrightInfo
Copyright 2009 S. Karger AG, Basel.
pubmed:issnType
Electronic
pubmed:volume
76
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
151-6
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.
pubmed:affiliation
Drug Development Unit, Royal Marsden Hospital, London and Surrey, UK. hendrik-tobias.arkenau@icr.ac.uk
pubmed:publicationType
Journal Article